Cost-effectiveness of quadrivalent human papillomavirus vaccination in adolescent girls

The human papillomavirus (HPV) infection is one of the major risk factor of development of genital warts, a cervical dysplasia, a cervical cancer, and also some other oncologic diseases. The usage of quadrivalent HPV vaccine in girls reduces the corresponding case rate and the mortality significantly.

The objective of this study is to analyze the cost-effectiveness of quadrivalent HPV vaccination cases of 12-yearold girls in Russian Federation.

Materials and methods. A Markov model is used on the basis of epidemiological data in Russian Federation. The cost-effectiveness was estimated from societal perspective. We assumed that the effect of vaccination remains throughout all life. The analysis is performed for survival of 12-year-old girls. We considered only effect in the vaccinated population. Costs for therapy of the diseases associated with HPV infection corresponded to compulsory health insurance rates across St. Petersburg for 2016. Costs and life expectancy have been discounted for 3,5% a year.

Results. Quadrivalent HPV vaccination of 12-year-old girls in Russian Federation will allow to prevent counting on 10000 the vaccinated persons 293 cases of genital warts, 15 cases of pre invasive cervical cancer, 81 cases of invasive cervical cancer, 6 cases of vulvar cancer, 2 cases of vaginal cancer, 2 cases of anal cancer, 1 case of oropharyngeal cancer. In general, 49 cases of death caused by HPV infection on 10000 vaccinated girls would be prevented. The vaccination will provide cost reduction, caused by HPV-associated diseases, for 68% (58,38 million rubles on 10000 vaccinated), and 96% of the predicted prevented costs will be caused by decrease in incidence of cervical cancer. The quadrivalent HPV vaccination is associated with an incremental cost-effectiveness ratio (ICER) of 172 000 rubles per quality adjusted life-year (QALY) and 411 300 rubles per death caused by HPV-associated diseases.

Conclusions. Quadrivalent HPV vaccination of girls prior to the beginning of sex life could be considered in Russian Federation as an economically highly effective technology for preventing HPV-associated diseases.

1. La Vecchia S., Bosetti C., Lucchini F., et al. Cancer mortality in Europe, 2000– 2004, and an overview of trends since 1975 // Annals of Oncology 2010; 21: 1323– 1360.

2. Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoj. Zlokachestvennye novoobra-zovanija v Rossii v 2014 godu (zabolevaemost’ i smertnost’).- M.: MNIOI im. P.A. Gercena – filial FGBU «NMIRC» Minzdrava Rossii, – 2016.- 250 s.

3. Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoj. Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2015 godu. M.: MNIOI im. P.A. Gercena filial FGBU «NMIRC» Minzdrava Rossii, 2016.- 236 s.

4. Ljalina L.V. Jepidemiologicheskoe, social’noe i jekonomicheskoe obosnovanie vakcinacii protiv papillomavirusnoj infekcii v Sankt-Peterburge // Infekcija i immunitet 2014, T. 4, № 2, s. 181–186.

5. Kostin A.A., Starinskij V.V., Samsonov Ju.V., Asratov A.T. Analiz statisticheskih dannyh o zlokachestvennyh novoobrazovanijah, associirovannyh s virusom papillomy cheloveka // Issledovanija i praktika v medicine. 2016, t. 3, № 1, s. 66-78.

6. Sheljakina T.V., Leonov M.G., Nerodo G.A. Onkojepidemiologicheskie aspekty optimi-zacii profilaktiki raka shejki matki // Kubanskij nauchnyj medicinskij vestnik 2010; 2 (116): 103-107.

7. Aksel’ E.M. Sostojanie onkologicheskoj pomoshhi naseleniju Rossii i stran SNG v 2005 g. // Vestnik RONC im. N. N. Blohina RAMN 2007; 18 (2) (pril. 1): 8-51.

8. Urmancheeva A.F. Jepidemiologija raka vul’vy. Faktory riska i prognoza // Praktiche-skaja onkologija 2006; 7 (1): 189- 196.

9. Leval A., Herweijer E., Ploner A., et al. Quadrivalent human papillomavirus vaccine effec-tiveness: A Swedish National Cohort Study // JNCI Journal of the National Cancer Institute Advance Access published March 13, 2013.

10. Tabrizi S., Brotherton J., Kaldor J., et al. Fall in human papillomavirus prevalence following a National Vaccination Program // The Journal of Infectious Disease 2012; 206: 1645 – 1651.

11. Smith G., Travis L. Getting to know human papillomavirus (HPV) and the HPV vaccines // JAOA 2011; 111 (Suppl. 2): 29-34.

12. de Sanjosé S., Serrano B., Castellsagué X., Brotons M., Muñoz J., Bruni L., Bosch F.X. Hu-man Papillomavirus (HPV) and Related Cancers in the Global Alliance for Vaccines and Immunization (GAVI) Countries. A WHO/ICO HPV Information Centre Report. Vaccine 2012;30 (Suppl 4). Available at www.who.int/hpvcentre

13. Xian Wen Jin, Lipold L., Sikon A., Rome E. Human papillomavirus vaccine: safe, effective, underused // Cleveland Clinic Journal of Medicine 2013; 80 (1): 49-60.